|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BIRC7 |
Gene summary for BIRC7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BIRC7 | Gene ID | 79444 |
| Gene name | baculoviral IAP repeat containing 7 | |
| Gene Alias | KIAP | |
| Cytomap | 20q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | Q96CA5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79444 | BIRC7 | PTC03 | Human | Thyroid | PTC | 2.36e-17 | 7.57e-01 | 0.1784 |
| 79444 | BIRC7 | ATC2 | Human | Thyroid | ATC | 3.71e-05 | 5.38e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1903320113 | Thyroid | PTC | regulation of protein modification by small protein conjugation or removal | 148/5968 | 242/18723 | 4.49e-21 | 8.10e-19 | 148 |
| GO:0031396113 | Thyroid | PTC | regulation of protein ubiquitination | 128/5968 | 210/18723 | 3.06e-18 | 3.27e-16 | 128 |
| GO:190332210 | Thyroid | PTC | positive regulation of protein modification by small protein conjugation or removal | 73/5968 | 138/18723 | 2.34e-07 | 4.11e-06 | 73 |
| GO:00313989 | Thyroid | PTC | positive regulation of protein ubiquitination | 63/5968 | 119/18723 | 1.47e-06 | 2.08e-05 | 63 |
| GO:0043281113 | Thyroid | PTC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 99/5968 | 209/18723 | 1.93e-06 | 2.64e-05 | 99 |
| GO:2000116113 | Thyroid | PTC | regulation of cysteine-type endopeptidase activity | 108/5968 | 235/18723 | 3.99e-06 | 4.99e-05 | 108 |
| GO:0052547113 | Thyroid | PTC | regulation of peptidase activity | 191/5968 | 461/18723 | 7.82e-06 | 9.02e-05 | 191 |
| GO:0052548113 | Thyroid | PTC | regulation of endopeptidase activity | 174/5968 | 432/18723 | 1.20e-04 | 9.55e-04 | 174 |
| GO:0043154112 | Thyroid | PTC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 40/5968 | 78/18723 | 2.83e-04 | 2.01e-03 | 40 |
| GO:2000117112 | Thyroid | PTC | negative regulation of cysteine-type endopeptidase activity | 43/5968 | 86/18723 | 3.49e-04 | 2.40e-03 | 43 |
| GO:00718872 | Thyroid | PTC | leukocyte apoptotic process | 48/5968 | 106/18723 | 2.58e-03 | 1.32e-02 | 48 |
| GO:0051346112 | Thyroid | PTC | negative regulation of hydrolase activity | 146/5968 | 379/18723 | 3.33e-03 | 1.62e-02 | 146 |
| GO:0045861113 | Thyroid | PTC | negative regulation of proteolysis | 136/5968 | 351/18723 | 3.54e-03 | 1.71e-02 | 136 |
| GO:190332034 | Thyroid | ATC | regulation of protein modification by small protein conjugation or removal | 152/6293 | 242/18723 | 9.76e-21 | 1.71e-18 | 152 |
| GO:003139634 | Thyroid | ATC | regulation of protein ubiquitination | 132/6293 | 210/18723 | 3.13e-18 | 3.98e-16 | 132 |
| GO:190332218 | Thyroid | ATC | positive regulation of protein modification by small protein conjugation or removal | 77/6293 | 138/18723 | 6.67e-08 | 1.17e-06 | 77 |
| GO:003139818 | Thyroid | ATC | positive regulation of protein ubiquitination | 67/6293 | 119/18723 | 2.95e-07 | 4.46e-06 | 67 |
| GO:004328133 | Thyroid | ATC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 102/6293 | 209/18723 | 3.61e-06 | 4.03e-05 | 102 |
| GO:005254734 | Thyroid | ATC | regulation of peptidase activity | 200/6293 | 461/18723 | 6.25e-06 | 6.52e-05 | 200 |
| GO:200011633 | Thyroid | ATC | regulation of cysteine-type endopeptidase activity | 111/6293 | 235/18723 | 9.41e-06 | 9.41e-05 | 111 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BIRC7 | SNV | Missense_Mutation | novel | c.207G>T | p.Glu69Asp | p.E69D | Q96CA5 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-AR-A2LK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | PD |
| BIRC7 | SNV | Missense_Mutation | c.409G>A | p.Gly137Arg | p.G137R | Q96CA5 | protein_coding | deleterious(0.04) | possibly_damaging(0.617) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| BIRC7 | SNV | Missense_Mutation | rs748222291 | c.865N>A | p.Val289Ile | p.V289I | Q96CA5 | protein_coding | tolerated(1) | benign(0.009) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| BIRC7 | SNV | Missense_Mutation | rs190075934 | c.773N>A | p.Arg258His | p.R258H | Q96CA5 | protein_coding | tolerated(0.13) | benign(0.019) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BIRC7 | SNV | Missense_Mutation | rs190075934 | c.773N>A | p.Arg258His | p.R258H | Q96CA5 | protein_coding | tolerated(0.13) | benign(0.019) | TCGA-AA-3521-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| BIRC7 | SNV | Missense_Mutation | rs376332500 | c.730N>T | p.Arg244Trp | p.R244W | Q96CA5 | protein_coding | deleterious(0) | possibly_damaging(0.798) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BIRC7 | SNV | Missense_Mutation | rs761744542 | c.415N>A | p.Asp139Asn | p.D139N | Q96CA5 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-CK-4952-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| BIRC7 | SNV | Missense_Mutation | rs61737394 | c.731N>A | p.Arg244Gln | p.R244Q | Q96CA5 | protein_coding | tolerated(0.29) | benign(0.015) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BIRC7 | SNV | Missense_Mutation | rs778417811 | c.179G>A | p.Arg60Gln | p.R60Q | Q96CA5 | protein_coding | tolerated(1) | benign(0.019) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BIRC7 | SNV | Missense_Mutation | novel | c.139N>A | p.Ala47Thr | p.A47T | Q96CA5 | protein_coding | tolerated(0.53) | benign(0.006) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 79444 | BIRC7 | PROTEASE INHIBITOR, TUMOR SUPPRESSOR, DRUG RESISTANCE | antagonist | 223366066 | GDC-0152 | |
| 79444 | BIRC7 | PROTEASE INHIBITOR, TUMOR SUPPRESSOR, DRUG RESISTANCE | antagonist | AT-406 | AT-406 | |
| 79444 | BIRC7 | PROTEASE INHIBITOR, TUMOR SUPPRESSOR, DRUG RESISTANCE | CISPLATIN | CISPLATIN | 23188704 | |
| 79444 | BIRC7 | PROTEASE INHIBITOR, TUMOR SUPPRESSOR, DRUG RESISTANCE | PMID25980951-Compound-6 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |